Australia markets closed

TScan Therapeutics, Inc. (TCRX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
8.86+0.22 (+2.49%)
As of 12:22PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 457.26M
Enterprise value 357.65M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)26.96
Price/book (mrq)3.03
Enterprise value/revenue 16.99
Enterprise value/EBITDA -4.47

Trading information

Stock price history

Beta (5Y monthly) 0.90
52-week change 3260.42%
S&P500 52-week change 322.43%
52-week high 39.09
52-week low 31.93
50-day moving average 37.26
200-day moving average 34.87

Share statistics

Avg vol (3-month) 3211k
Avg vol (10-day) 3193.92k
Shares outstanding 548.59M
Implied shares outstanding 65.14M
Float 822.43M
% held by insiders 10.79%
% held by institutions 173.33%
Shares short (15 Apr 2024) 4419.69k
Short ratio (15 Apr 2024) 42
Short % of float (15 Apr 2024) 41.46%
Short % of shares outstanding (15 Apr 2024) 40.88%
Shares short (prior month 15 Mar 2024) 4188.34k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-296.17%

Management effectiveness

Return on assets (ttm)-24.79%
Return on equity (ttm)-71.29%

Income statement

Revenue (ttm)21.05M
Revenue per share (ttm)0.32
Quarterly revenue growth (yoy)133.00%
Gross profit (ttm)N/A
EBITDA -88.1M
Net income avi to common (ttm)-89.22M
Diluted EPS (ttm)-1.36
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)192.04M
Total cash per share (mrq)4.01
Total debt (mrq)92.43M
Total debt/equity (mrq)61.27%
Current ratio (mrq)6.51
Book value per share (mrq)3.15

Cash flow statement

Operating cash flow (ttm)-61.36M
Levered free cash flow (ttm)-41.83M